Stock Movers: Abivax, Siemens Energy, Mowi (Podcast)

Abivax surged as much as 27% after a clinical-trial update eased concerns that its lead experimental cancer drug could cause cancer-related side effects. Siemens Energy (and other power-exposed industrials) were supported by a narrative that AI-led capital spending is broadening across grid, data-center, defense, and mining end-markets. In contrast, Mowi ASA fell 3.7% on volume about 3x the average for this time of day, signaling near-term downside despite mixed broader tape.

Analysis

The cleaner read-through is that AI spend is migrating from the obvious chip winners into the bottleneck layer: power generation, grid hardware, switchgear, transformers, and cooling. That favors Siemens Energy and adjacent names with backlog visibility and service revenue, while the market may be overvaluing pure semis if utility interconnect and power delivery become the pacing item for data-center commissioning. The second-order effect is that the next leg of AI capex could lift the less crowded industrials multiple before it lifts the already-owned GPU complex.

ABVX looks like a classic biotech de-risking trade: the move can persist for days if short interest is crowded, but it only becomes durable if the next dataset confirms the safety profile across a bigger sample. The market is likely still discounting tail risk rather than peak efficacy, so the upside is less about a fundamental step-change and more about probability re-rating. Falsifier: any renewed signal in the full safety package or a regulator asking for more follow-up.

Mowi’s move reads more like margin-cycle noise than a thesis change unless it is tied to weaker salmon pricing or currency. If so, the damage can leak into aquaculture peers and feed suppliers over the next 1-3 quarters, but it is not usually a same-day macro signal. Contrarian view: consensus may be overreacting to a single loss print while underestimating how quickly supply discipline can tighten the sector again once spot prices stabilize.

Key Decisions for Investors

• Overweight SMNEY on 1-3 month pullbacks; this is a cleaner AI-capex beneficiary than crowded semiconductor proxies. Trim if order growth or backlog conversion slows.
• Use ABVX only as a tactical event trade, preferably via a small call-spread or tight-risk equity position into the next disclosure. Take profits quickly if the stock gaps on short covering; exit on any renewed safety concern.
• Prefer a basket of power-infrastructure names such as ETN, GEV, and VRT for a 6-18 month structural AI buildout theme. The risk/reward is better than chasing the most owned AI chip names.
• No immediate trade in Mowi; watch salmon spot pricing and NOK for 2-4 weeks before acting. If both remain weak, consider a short versus broader European defensives.